system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: ADAM Proteins, ADAM12 Protein, Adult, Case-Control Studies, Down Syndrome, Efficiency, False Positive Reactions, Female, Gestational Age, Humans, Mass Screening, Membrane Proteins, Pregnancy, Pregnancy Trimester, Second, Prenatal Diagnosis, Young Adult.
user
Is aDAM12 an effective marker in the second trimester of pregnancy for prenatal screening of Down syndrome? Context: To estimate the use of maternal serum ADAM12 as a second-trimester Down syndrome serum marker. Samples from a total of 46 Down syndrome pregnancies and 184 unaffected singleton pregnancies matched for gestational age and maternal weight were retrieved from storage and measured for ADAM12; 35 false-positive pregnancies were included among the controls to assess reductions in false-positive rates by inclusion of ADAM12 in the risk calculation of an algorithm that used alpha-fetoprotein (AFP) and human chorionic gonadotrophin (hCG) (double screen). ADAM12 was measured and expressed as multiple of the gestation-specific median (MoM) and corrected for maternal weight. The median ADAM12 level in the affected pregnancies was 1.26 MoM compared with 1.0 MoM in the unaffected control pregnancies (p < 0.05). In unaffected pregnancies, there was a significant correlation between ADAM12 and AFP (r = 0.314) but not hCG (r = 0.018). Statistical modeling predicted that ADAM12 as a second serum marker could increase the detection rate from 48 to 85%, while reducing the false-negative and false-positive rates.
assistant
ADAM12 can be used as an effective second-trimester serum marker for prenatal screening of Down syndrome. Final Decision: yes